- Joined
- Feb 18, 2014
- Messages
- 696
- Reaction score
- 553
Stimulates the metabolism of body fat.
Anyone try this yet? My trt clinic just started offering it and the below information is from an email I received from them:
AOD9604 is a modified version of fragments 176-191 of Human Growth Hormone which harbors the fat reducing activity of HGH, without its negative effects.
It was developed as an anti obesity drug in the early 2000’s. AOD9604 stimulates the metabolism of body fat, the first of its kind in the world. All other obesity drugs artificially reduce appetite or food absorption.
This peptide is valued for the fact that it has limited effects beyond fat burning and does not affect IGF1 levels or insulin levels that are found when dosing HGH in higher dosages.
Phase 2b clinical trials were completed in Australia testing the drug in 300 obese individuals. The results of the peptide being administered once daily for 12 weeks showed the drug tripled weight loss when compared to placebo. Fat-loss was reported to continue during the trial period which indicates that a resistance to AOD9604 is unlikely and that longer treatment would result in even greater weight loss.
To date over 6 human clinical trials have been done comprising of over 1300 individuals on the safety and efficacy of orally administered AOD9604.
Anyone try this yet? My trt clinic just started offering it and the below information is from an email I received from them:
AOD9604 is a modified version of fragments 176-191 of Human Growth Hormone which harbors the fat reducing activity of HGH, without its negative effects.
It was developed as an anti obesity drug in the early 2000’s. AOD9604 stimulates the metabolism of body fat, the first of its kind in the world. All other obesity drugs artificially reduce appetite or food absorption.
This peptide is valued for the fact that it has limited effects beyond fat burning and does not affect IGF1 levels or insulin levels that are found when dosing HGH in higher dosages.
Phase 2b clinical trials were completed in Australia testing the drug in 300 obese individuals. The results of the peptide being administered once daily for 12 weeks showed the drug tripled weight loss when compared to placebo. Fat-loss was reported to continue during the trial period which indicates that a resistance to AOD9604 is unlikely and that longer treatment would result in even greater weight loss.
To date over 6 human clinical trials have been done comprising of over 1300 individuals on the safety and efficacy of orally administered AOD9604.


